Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3846469 | 0.86 | HTR7 (0.45) | HTR7DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL3844088 | 0.83 | ADRA2C (0.45) | HTR7DRD2DRD3 | |
| SCHEMBL3848601 | 0.82 | DRD2 (0.40) | HTR7DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL17219787 | 0.82 | DRD3 (0.41) | HTR7DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL3844666 | 0.82 | DRD2 (0.40) | HTR7DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL3845098 | 0.80 | DRD2 (0.48) | HTR7DRD2DRD3KCNH2 | |
| SCHEMBL3849898 | 0.80 | DRD2 (0.58) | HTR7DRD2DRD3 | |
| SCHEMBL3845294 | 0.80 | DRD2 (0.43) | HTR7DRD2DRD3 | |
| SCHEMBL3847168 | 0.80 | DRD2 (0.47) | AGXTDRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL3848596 | 0.79 | DRD2 (0.42) | HTR7DRD2DRD3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
| EP-1870405-A1 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870405-A1 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | AGXT 4732/4885HTR7 233/4885DRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.